A systematic review has shed light on the complex relationship between metabolism and the immune system in glioma, a type of brain tumor. The review found that metabolic reprogramming—changes in how cells use energy—and the tumor's immune environment are deeply connected. Together, they drive tumor growth, progression, and resistance to treatment.
The analysis looked at multiple metabolic pathways, including those involving nucleotides, amino acids, and lipids. These pathways were closely linked to how immune cells infiltrate the tumor, how the tumor evades the immune system, and patient outcomes. The findings suggest that targeting these metabolic pathways could help improve immune-based therapies.
This review provides a framework for understanding the metabolic-immune interplay in glioma. It identifies promising targets for precision therapy and future clinical translation. However, the evidence is based on associations, not cause-and-effect, and no specific clinical outcomes or treatment benefits can be inferred from this review alone.
